Astrin Biosciences released Certitude™, a blood-based test using deep proteomic analysis to identify breast cancer-associated protein signals in the blood.
Public source
Publisher name
Public post
In a recent podcast conversation, Dr. Barbara Levy, MD, FACOG, FACS shared a vision for what it could mean to give more women greater clarity about their breast health—p…
Company
Astrin Biosciences
To lead in cancer intelligence and early detection
- Industry
- Medical and Diagnostic Laboratories
- Location
- St. Paul, US
- Company size
- 11–50 employees
About Astrin Biosciences
Astrin Biosciences is a cancer intelligence company built to push the boundaries of technology – accelerating early detection and advancing cancer care. Astrin’s breakthrough cancer tests analyze the early signals in over 8,000 proteins to reveal what most tests miss: the earliest molecular signals in cancer development. Astrin Biosciences was founded on a bold idea: that health decisions should be based not just on what’s happening inside the body, but on the reality of the person living in it. Our Mission is to lead in cancer intelligence and early detection.
See moreLatest activity
Latest activity from Astrin Biosciences
3 signals
Products & Services
Astrin Biosciences developed Certitude™, a blood-based cancer detection platform using proteomic biomarkers associated with breast cancer to complement established imaging pathways.
Research & Knowledge
Astrin Biosciences highlighted its perspectives on cancer care in the latest The Pulse article by HLTH Inc. and Alexa Mikhail.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
GoPath Diagnostics
GoPath Diagnostics launched ProstateNow, a germline test for prostate cancer combining multi-gene analysis with a risk-focused approach to support real-world decision-making.
Products & Services
Precision Epigenomics
Precision Epigenomics announced the EPISEEK multi-cancer early detection test.
Products & Services
Caris Life Sciences
Caris Life Sciences introduced Caris Detect, a multi-cancer early detection blood test combining ultra-deep whole genome and whole transcriptome sequencing with advanced AI trained on over 1 million patient cases and 50 billion molecular markers.
Products & Services
OncoOptima
OncoOptima launched OncoChoice, a drug activity test measuring how a patient's own cancer cells respond to specific treatments, reporting cell-activity data back to the ordering physician.
Products & Services
Cizzle Bio, Inc.